Arcus Biosciences (NYSE: RCUS)
Arcus Biosciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Arcus Biosciences Company Info
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
News & Analysis
Why Arcus Biosciences Stock Vaulted Higher in November
Arcus was one of the few winners in the turbulent biotech space last month.
Why Arcus Biosciences Stock Is On Fire Today
Gilead Sciences has decided to exercise its options for three of the biotech's oncology programs.
Why Arcus Biosciences' Big Reveal Wasn't Very Exciting
No news from Arcus Biosciences is bad news for the company and other industry heavyweights.
Here's Why Arcus Biosciences Stock Is Rising Today
Investors expecting Gilead Sciences to license Arcus Biosciences' lead asset could be in for an unpleasant surprise.
Here's Why Arcus Biosciences Stock Gained as Much as 15.9% Today
The development-stage biopharma is bouncing back from a recent stock dip.
Here's Why Arcus Biosciences Is Losing Ground Today
Investors expecting a buyout offer were disappointed by the collaboration agreement Gilead Sciences offered.
Gilead Sciences Signs $2 Billion Partnership with Arcus Biosciences
The deal gives Gilead access to a new pipeline of potential cancer immunotherapies.
Report: Gilead Is Considering Taking a Stake in Arcus Biosciences
The two companies are apparently discussing either an equity purchase, or some form of cooperation.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.